Skip to main content
. Author manuscript; available in PMC: 2014 Mar 28.
Published in final edited form as: Annu Rev Med. 2012 Nov 28;64:407–425. doi: 10.1146/annurev-med-120611-144851

Figure 3. Ataluren manifests a bell-shaped dose response.

Figure 3

Myotubes from a phase 2a nmDMD patient were cultured in the presence of different concentrations of ataluren and assayed for the accumulation of dystrophin and a control protein by immunofluorescence assays.